Jais Rose Bjelke, PhD, earned his doctorate in Haemostasis Biochemistry in 2006 after completing degrees in Human Biology and Molecular Biology. He has spent over two decades at Novo Nordisk, where he currently serves as Senior Principal Scientist in the Therapeutics Discovery research unit. Jais has contributed to multiple biopharmaceutical programs, including the development of Rebinyn®/Refixia® (nonacog beta pegol), a long-acting factor IX therapy approved by FDA and EMA, and Mim8, a bispecific FVIII-mimetic antibody now in phase 3 trials. His current focus is on innovative modalities for haemophilia and other diseases, exemplified by Inno8, a first-in-class oral Factor VIIIa-mimetic candidate.
Jais Bjelke
